Based on these findings we designed experiments expecting that enhanced UGT1A expression confers a protective effect during hepatic steatosis, NASH development and, as a consequence, in the progression to liver fibrosis. The gene discussed is UGT1A1; the disease is metabolic dysfunction-associated steatohepatitis.